What did @thenutritionnarc actually say?
The creator argued that giving an 11-year-old Ozempic is "a pretty good idea" in principle, mainly because it sidesteps the psychological damage of putting kids on diets. Their core logic: a weekly injection that suppresses appetite is less traumatic than teaching a child to count calories. They also stated that "Wegovy is actually approved for everyone who was above 12 years old," and walked back slightly by saying the girl in question "wasn't even that prime candidate" because she wasn't severely overweight. They framed GLP-1 treatment as a last resort, not a first line, but still defended it as a legitimate option for families who have exhausted everything else.
That's a more nuanced take than the headline suggests, but there are still some real problems with the framing worth unpacking.
Does the science back this up?
Partially, yes. The FDA approval claim is accurate, and the trial data supporting it is solid. But the idea that a weekly injection is inherently less psychologically risky than behavioral intervention oversimplifies a complicated picture.
In 2022, the FDA approved semaglutide 2.4mg (Wegovy) for chronic weight management in adolescents aged 12 and older with obesity, based on the STEP TEENS trial (Weghuber et al., 2022, New England Journal of Medicine). That trial showed a 16.1% reduction in BMI among adolescents on semaglutide versus a 0.6% reduction in the placebo group. That is a meaningful clinical result. The drug works in kids, at least over a 68-week window.
What the creator glosses over is that "approved for 12 and older" does not mean risk-free or automatically appropriate. The STEP TEENS trial excluded children under 12, had a relatively short follow-up, and did not capture long-term effects on bone density, growth, or pubertal development. Pediatric endocrinologists emphasize that these unknowns matter when you're treating a body that is still developing.
What did they get wrong (or right)?
They got the approval age right. Wegovy's FDA label does cover adolescents 12 and older with a BMI at or above the 95th percentile for age and sex. That is not misinformation, and credit where it's due for not inflating the claim.
They got the psychology argument partially right too. There is genuine evidence that restrictive dieting in childhood is associated with disordered eating. Neumark-Sztainer et al. (2006, Journal of the American Dietetic Association) found that adolescents who dieted were more likely to engage in binge eating five years later. The creator's concern about calorie-counting trauma is not invented.
However, framing the choice as "traumatizing diet or weekly injection" is a false binary. Current clinical guidelines from the American Academy of Pediatrics (Hampl et al., 2023, Pediatrics) recommend intensive health behavior and lifestyle treatment as the foundation, with pharmacotherapy as an adjunct for adolescents 12 and older when behavioral approaches are insufficient. Medication does not replace behavioral support; it works alongside it. The creator's framing makes that relationship sound more optional than it is.
Also worth flagging: the creator applied reasoning about 12-year-olds to an 11-year-old. The child in the original story was 11, which is below the approved age threshold. That is not a minor detail.
What should you actually know?
If you are a parent navigating this, the conversation belongs in a pediatric endocrinologist's office, not in a TikTok comment section. That is not a dodge; it reflects how genuinely complex this decision is.
Semaglutide for adolescent obesity is an active area of clinical research, and the early data is promising. But "approved" and "appropriate for your specific child" are different questions. Weight regain after stopping GLP-1 medications is well-documented in adults (Wilding et al., 2022, Diabetes, Obesity and Metabolism), and there is no long-term adolescent data yet on what happens when a 12-year-old stops the medication at 16 or 18.
The creator also conflates Ozempic (semaglutide 1mg or 2mg, approved for type 2 diabetes) with Wegovy (semaglutide 2.4mg, approved for weight management). These are different FDA-approved products with different labeled indications, even though they share the same active molecule. That distinction matters in a regulated context.
Bottom line: GLP-1 therapy in adolescents is a legitimate medical option for the right patient with the right clinical oversight. It is not a shortcut, and it is not a substitute for the behavioral and family-based support that actually shapes long-term health outcomes.